U.S. Patent Office Grants Dyax Corp.’s Request for an Interference with U.S. Patent No. 7,700,302 Issued to Adimab

Dyax Corp. (NASDAQ: DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that the United States Patent and Trademark Office (USPTO) Board of Patent Appeals and Interferences has granted the Company’s suggestion to declare an interference between Dyax’s U.S. Patent Application No. 12/625,337 and Adimab LLC’s U.S. Patent No. 7,700,302 (the ‘302 patent), both of which cover methods of displaying a library of antibodies on the surface of yeast cells.